N30 Pharmaceuticals Inc - CO Boulder, Boulder 80301

N30 Pharmaceuticals Inc entered the industry of in 2008 and has grown to employ 1 to 4 people, generating an annual revenue of $50.000.000 to $99.999.999. The NAICS classifies this business under the code 4242101, which describes it as a . For further clarification, the SIC classifies this business under the code 2834 and described it as a . The business provides service to the BOTH market.

To acquire more information, please contact Charles Scoggin, Chief Executive Officer by calling (303) 440-8399 during business hours. You can also write to the business’ Single Location at 3122 Sterling Circle # 200, Boulder, Colorado CO 80301. You can also visit the company’s website at n30pharma.com. View this business’ social media profiles on Twitter or on Facebbok .

Company: N30 Pharmaceuticals Inc
Representative: Charles Scoggin, Chief Executive Officer
Place of Business: 3122 Sterling Circle # 200, Boulder, CO 80301
Contact Number: (303) 440-8399
Website: n30pharma.com
Type of Service:
SIC Number: 2834
NAICS Number: 4242101
Locality: Single Location
Market Type: B2B & B2C
Began: 2008
Income/Year: $50.000.000 to $99.999.999
Laborers: 1 to 4
Share This Company:

N30 Pharmaceuticals Inc is a company operating from Boulder, Colorado providing professional and relevant BOTH variables. It was founded in 2008 and registered with the SIC code 2834 as , and with the NAICS code 4242101 as .

With a current employee count of 1 to 4, N30 Pharmaceuticals Inc has gone to report making $50.000.000 to $99.999.999 per annum on its journey towards growth. This company invites you to contact its representative Charles Scoggin, Chief Executive Officer at (303) 440-8399 for related queries, or to locate its Single Location using the coordinates 40.03214,-105.22721.

The Single Location can also be found at the street address 3122 Sterling Circle # 200 in Boulder, Colorado 80301 and can be engaged online through the company website at n30pharma.com, the company Twitter , and Facebook page .